The mechanism of action/pharmacodynamics of ELIDEL Cream and the inflammatory cascade.6,8

Targets Cells Involved in Skin InfIammation

  • The mechanism of action of ELIDEL Cream in eczema is unknown.6
  • In vitro, it has been demonstrated that pimecrolimus inhibits calcineurin and thus inhibits
    T cell activation by blocking the transcription of inflammatory cytokines.6,8*
  • Pimecrolimus has an immunosuppressant action and targets cells involved in skin inflammation.6

*The clinical significance of in vitro data has not been established.

With ELIDEL, systemic absorption of pimecrolimus is low. Learn More.

See More


ELIDEL® (pimecrolimus) Cream 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.



Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established. Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including ELIDEL Cream.